Q1 2026 earnings beat sends Abbott stock higher by 3.04%

Traders Union
All News
Financial News
Abbott rises 3.04% to $85.07 today

Highlights

Abbott outperformed Q1 2026 expectations with $11.16 billion revenue and $1.15 EPS, demonstrating underlying operational strength.
Revised 2026 EPS outlook reflects dilution from the Exact Sciences acquisition and legal uncertainties in infant formula operations, impacting risk perception.
Bearish signals from trend and momentum indicators dominate, with price consolidating below resistance and a high probability of further downside toward $82.00.

Sentiment buoyed by earnings beat and institutional repositioning

Abbott's shares are drawing support from first quarter 2026 results, as the company reported revenue of $11.16 billion and earnings per share of $1.15, both surpassing market expectations and highlighting operational resilience. The recent declaration of a $0.63 per share quarterly dividend, payable May 15, 2026, extends Abbott's dividend streak and appeals to income-focused investors, contributing to the stock's attractiveness. Ongoing factors such as a legal verdict in the company's baby formula business and a downward revision of Abbott's 2026 adjusted EPS outlook, partly reflecting the dilutive impact of the Exact Sciences acquisition, are also in play. Changes in institutional holdings, including Securian Asset Management significantly decreasing its stake and Kepler Cheuvreux Suisse SA initiating a new position, reflect shifts in perception as market participants balance risk and opportunity.

Resistance limits as bearish momentum and oversold signals conflict

At $85.07, ABT is trading under its SMA-20 at $91.61, SMA-50 at $100.57, and SMA-200 at $119.40. The Ichimoku Kijun line at $92.91 offers immediate resistance. Intraday price action has held near the upper end of today’s $83.18–$84.88 range following an initial upward gap, with volatility described as moderate. Bearish momentum remains dominant, as both MACD and ADX reflect a selling trend. RSI, Stoch RSI, and CCI signal pronounced oversold conditions, while BBP indicates seller control over intraday movement. These readings highlight a divergence between a possible short-term rebound and established trend direction.

Sideways bias dominates as breakout risks remain subdued

Over the short term, ABT is expected to trade within a typical volatility band from $82.00 to $87.00. The baseline scenario envisions sideways movement below resistance, with a probability of a sustained price increase remaining low due to prevailing weekly bearish signals. A bullish breakout would require a move above $92.91, while renewed negative momentum could see a test of support near $82.00 or below.

Anton Kharitonov, analyst at Traders Union, sees limited upside in Abbott Laboratories despite strong Q1 2026 results and steady dividends. He notes that technical pressure is persistent, with prices stuck below all major moving averages and legal risks weighing on sentiment. Institutional flows are mixed, supporting a cautious stance. "Unless ABT clears $92.91, I expect sideways or lower movement — this is not a bullish setup yet."

Earlier, analysts noted that Abbott Laboratories was exhibiting persistent bearish momentum, with technical indicators signaling strong downside pressure. While the current analysis acknowledges ongoing weakness, recent earnings strength and dividend continuity suggest investors should closely monitor for a potential shift if the stock sustains an advance above $92.91, which would challenge the prevailing downtrend.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.